GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 43.02B USD.
Alto dividendo
La empresa es una gran pagadora de dividendos. Su ratio de pago de dividendos más reciente es del 96.66%.
Dividendo estable
La empresa ha pagado dividendos de forma regular durante los últimos 5 años. Su ratio de pago de dividendos más reciente es del 96.66%.
Infravalorada
El PE más reciente de la empresa es 13.08, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 393.46M acciones, lo que supone una reducción del 5.63% con respecto al trimestre anterior.
En posesión de Brandes Investment
El inversor estrella Brandes Investment posee 8.04M acciones de este valor.
